Drug Profile
CV 9202
Alternative Names: BI 13618409; BI 1361849; CV-9202Latest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator CureVac; Ludwig Institute for Cancer Research
- Developer Boehringer Ingelheim; Cancer Research Institute; CureVac; Ludwig Institute for Cancer Research
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 29 Oct 2021 Ludwig Institute for Cancer Research in collaboration with Boehringer Ingelheim and MedImmune completes the phase I/II trial in Non-small cell lung cancer in USA (NCT03164772)
- 25 Sep 2020 CV 9202 is still in phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (Intradermal) (NCT03164772)
- 25 Sep 2020 CV 9202 is still in phase I/II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, In adults, In the elderly) in Spain (Intradermal) (EudraCT2015-001477-41)